joimax® continues strong growth trend in 2017 with launch of its MultiZYTE® Facet and SI Joint treatment Set in the US and also obtains full approval of its Endovapor® 2 system in China

Karlsruhe, Germany – February 8, 2018 – the joimax® group announces very strong sales figures for 2017. The German based market leader of technologies and training methods for endoscopic minimally invasive spinal surgery shows a jump of almost 80% vs. 2016 in the U.S. Consolidated sales show a growth of nearly 30%, which reflects its CAGR of 35% since 2008.

“joimax® is in line with its top-line plans as well as with its EBIT growth projections”, states Rainer Schmitz, the long-standing CFO of the joimax® GmbH. “The company is now active in 50 countries and enjoys a strong reputation in Europe, Asia and the U.S.”

Based on the inclusion of the newly created AMA CPT code 62380 for endoscopic decompression of the lumbar spine as of January 1st, 2017, and the worldwide increasing adoption rate of the joimax® procedures in general, the company is gaining a strong foothold throughout the U.S.. The acceptance of endoscopic minimally invasive spine surgery techniques and their benefits to both the patients and the surgeons are steadily growing worldwide.

The understanding and therapy of SI Joint is a rapidly growing new field worldwide. joimax® faces this growing area of unmet needs with its MultiZYTE® Facet and SI Joint Treatment Set in this market segment. The upcoming 3rd International Conference on Sacroiliac Joint Surgery (ICSJS), taking place in Tampa, FL from Feb. 21 to 24, 2018 gives attendees the opportunity to further enhance the level of understanding of the sacroiliac joint and to participate in a cadaver workshop at CAMLS learning center.

Further success in Asia is a result of the recent approval of the joimax® Endovapor® 2 Multi Radio Frequency System also in China, where joimax® has already been successfully in the market for 10 years.

“With this latest approval we now can market all our systems in this important country, which is a great step towards more targeted patient care” states Wolfgang Ries, Founder and CEO of joimax®.

The Endovapor® 2 generates electrical power for monopolar and bipolar cutting and coagulation of tissue structures in surgical operations. The device is an all-in-one generator with specially integrated programs for spinal surgery with interdisciplinary application. It is equipped with two monopolar and two bipolar sockets and an easy and intuitive touchpad technology.  With arc control for safe application and easy neutral electrode monitoring, it combines a variety of electro-surgical modes and effects.

joimax Endoscopic Tower

joimax® Signs National Distribution Partner in Taiwan

Karlsruhe (GER), 26 June 2020 – joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is pleased to announce a new countrywide distributor in Taiwan, Hi-Clearance Inc. With the aim of building an effective, long-term relationship, the strategic supplier partnership is a further milestone in the international growth of joimax® .

joimax® Signs National Distribution Partner in Taiwan

“Hi-Clearance is our ideal sales and service partner,” says joimax® CEO and Founder Mr. Wolfgang Ries. With their streamlined structure and process in place, we are confident joimax® will penetrate this new market very successfully”.

Hi-Clearance Inc. has over 239 employees, and is a well-known supplier of medical materials and equipment in Taiwan. “We are very pleased about the new strategic partnership and are excited to continue the strong growth of both companies,” states Hi-Clearance Chairman Mr. John Lee and President Mr. Ernie Chen. “We are dedicated to establishing joimax® as the leading brand of endoscopic spine surgery in Taiwan.”

Hi-Clearance Inc. is headquartered in Taipei with four other branches spread across the country. The main business includes products for Hemodialysis, Critical Care, Dental, Cardiology, Homecare Devices, Nutrition and a major Spine Surgery Division. In 2019, sales were USD 107 million.